Biodesix (NASDAQ:BDSX – Get Free Report) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.75) per share and revenue of $27.49 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.
Biodesix (NASDAQ:BDSX – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.19. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. The firm had revenue of $26.86 million for the quarter, compared to analysts’ expectations of $26.03 million. On average, analysts expect Biodesix to post ($2.68) EPS for the current fiscal year and ($1.66) EPS for the next fiscal year.
Biodesix Trading Down 6.3%
NASDAQ:BDSX opened at $21.78 on Tuesday. The company has a market cap of $229.80 million, a P/E ratio of -6.87 and a beta of 0.56. Biodesix has a twelve month low of $5.26 and a twelve month high of $31.97. The business has a 50 day moving average price of $26.36 and a two-hundred day moving average price of $18.71. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on BDSX. Canaccord Genuity Group boosted their price objective on shares of Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. TD Cowen reaffirmed a “buy” rating and issued a $40.00 target price (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Biodesix in a research note on Thursday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $36.25.
Get Our Latest Analysis on Biodesix
Insiders Place Their Bets
In related news, Director Jack Schuler purchased 15,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was purchased at an average cost of $24.47 per share, for a total transaction of $367,050.00. Following the completion of the purchase, the director directly owned 555,810 shares in the company, valued at $13,600,670.70. This trade represents a 2.77% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased 42,600 shares of company stock valued at $1,033,062 in the last ninety days. 23.20% of the stock is owned by company insiders.
Biodesix Company Profile
Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.
Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.
Read More
- Five stocks we like better than Biodesix
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
